Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non–small cell lung cancer patients

Clinical trials on icotinib, a first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), have shown promising results as targeted therapy for non-small cell lung cancer (NSCLC). This study aimed to establish an effective scoring system to predict the one-year progressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Xueyun, Wang, Sufei, Xia, Hui, Chen, Hebing, Xu, Juanjuan, Meng, Daquan, Wang, Zhihui, Li, Yan, Yang, Lian, Jin, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289924/
https://www.ncbi.nlm.nih.gov/pubmed/37140694
http://dx.doi.org/10.1007/s10637-023-01329-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289924/
https://www.ncbi.nlm.nih.gov/pubmed/37140694
http://dx.doi.org/10.1007/s10637-023-01329-8

Ejemplares similares